Lumida
/REED
⌘K
REED

REED

REED
$1.00USD+1.01%+0.01 today

MARKET CAP

11.9M

P/E (TTM)

FWD P/E

DAY RANGE

$1 – $1

52W RANGE

$1
$12

The case for & against

Bull & Bear analysis

Bearish

Reed's, Inc. (NASDAQ: REED) operates within the non-alcoholic beverages sector, specializing in ginger-based drinks and mixers such as craft ginger ale and functional sodas. The company has established itself in the growing market for health-conscious beverages, seeking to capitalize on evolving consumer preferences towards natural and functional products. Recent strategic initiatives aim to enhance operational efficiency and distribution efficiency amidst competitive pressures and supply chain challenges, reinforcing its position within the market.

Bull says

  • New multifunctional soda line targets millennials and Gen Z.
  • Cash on hand grew to $10.4M; debt trimmed to $9.6M.
  • Delivery and handling expenses down 35% YoY improving efficiency.
  • 1,100 new retail placements broaden distribution network reach.
  • Uplisting to NYSE American increases institutional visibility and liquidity.
  • Tailwinds from rising demand for health-oriented beverages support growth.

Bear says

  • Net sales slid to $7.5M amid operational setbacks and lost placements.
  • Gross margin contracted to 20% from higher COGS and write-offs.
  • SG&A spending rose to $5M, intensifying margin erosion risk.
  • Operating cash flow was negative $3.8M, straining liquidity.
  • Rebuilding retailer trust may delay recovery of distribution points.
  • Elevated debt (~$9.3M) and low institutional backing heighten risks.

Earnings Call · Q4 2024 · Mgmt. Guidance

Updated 07-03-2026neutral

Transcript signals

Bull points

  • Gross profit for Q4 2024 increased to 2.9 million compared to 0.5 million for the same period in 2023. Gross margin was 30% compared to 4% in the year-ago quarter.
  • We reinforced our balance sheet, streamlined operations, and enhanced efficiencies laying the groundwork for sustained growth and profitability.
  • This capital infusion will enable us to maintain inventory at optimal levels, ensuring consistent order fulfillment rates and reducing the short order shipments that previously hindered our growth.

Bear points

  • Net sales for the fourth quarter of 2024 were 9.7 million compared to 11.7 million in the year-ago quarter. This decrease was primarily driven by short-order shipments due to prior inventory constraints.
  • Operating loss during the fourth quarter improved to 3.7 million or negative 25 cents per share compared to a loss of 5.0 million or negative $1.55 per share in the fourth quarter of 2023.
  • Modified EBITDA was negative 0.7 million in Q4 2024 compared to positive 43,000 in the year-ago period.
Read full transcript analysis ›